High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia

Leukemia and Lymphoma

Volumn 27, Issue 5-6, 1997, Pages 469-474

  Woolley, Ian ^a   Curtis, David ^b   Szer, Jeff ^c   Fairley, Christopher ^e   Vujovic, Olga ^e   Ugoni, Anthony ^d   Spelman, Denis ^e  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

Hepatosplenic candidiasis; HiDAC major risk factor; High dose cytosine arabinoside; Leukemia; Risk factors in leukemia

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GENTAMICIN; NYSTATIN; STEROID; TIMENTIN;

ACUTE LEUKEMIA; ADULT; AGE; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; STEROID THERAPY;

EID: 0031446183     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058313     Document Type: Article

References (23)

1. Anaissie, E. (1992). Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis, 14 (Suppl 1), S43-S53
2. von Eiff, M., Fahrenkamp, A., Roos, N., Fegler. W. and van de Loo, J. (1990). Hepatosplenic candidosis-a late manifestation of Candida septicemia. Mycoses, 33, 283-290.
3. Blade, J., Lopez-Guillermo, A., Rozman, C. et al. (1992). Chronic systemic candidiasis in acute leukemia. Ann Hematol, 64, 240-244.
4. Armstrong, D. (1993). Treatment of opportunistic fungal infections. Clin Infect Dis, 16, 1-7.
5. de Repentigny, L. (1992). Serodiagnosis of candidiasis, aspergillosis and cryptococcosis. Clin Infect Dis, 14 (Suppl 1), S11-12.
6. Meyer, R. D. (1992). Current role of therapy with amphotericin B. Clin Infect Dis, 14 (Suppl 1), S. 154-S160.
7. Flannery, M. T., Simmons. D. B., Saba, H. et al. (1992). Fluconazole in the treatment of hepatosplenic candidiasis. Arch Int Med. 152, 406-408.
8. Anaissie, E., Bodey, G. P., Kantarjian, H. et al. (1991). Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med, 91, 142-150.
9. Wingard, J. R. (1992). The use of fluconazole prophylaxis in patients with chemotherapy induced neutropenia. Leukaemia and Lymphoma, 8, 353-359.
10. Bishop, J. F., Mathews, J. P., Young, G. A. et al (1996). A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 1710-1717.
11. Bow, E. J., Loewen, R., Cheang, M. S. and Schacter, B. (1995). Invasive fungal disease in adults undergoing remission-induction therapy for AML: the pathogenetic role of the antileukemic regimen. Clin Infect Dis, 21, 361-369.
12. Cole, G. T., Lynn, K. T. and Seshan, K. R. et al. (1990). Evaluation of a murine model of hepatic candidiasis. J. Clin. Microbiol., 28, 1828-1841.
13. Sandovsky-Losica, H., Barr-Nea, L. and Segal, E. (1992). Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment. J Med Vet Mycol, 303, 219-231.
14. Walsh, T. J., Lee, J. W., Roulides. E. et al. (1992). Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: approaches to understanding investigational antifungal compounds for patients with neoplastic diseases. Clin Infect Dis, 14 (Suppl 1), S139-S147.
15. Nohmi, T., Abe, S., Tansho, S. and Yamaguchi.,H. (1994). Supression of anti-candida activity of murine and human neutrophils by glucocortcoids Microbiol. Immunol, 38, 977-982.
16. Heidenreich, S., Kubis, T., Schmidt, M. and Fegler, W. (1994). Glucocorticoid-induced alterations of monocyte defense mechanisms against Candida albicans. Cellular Immunology, 157, 320-327
17. Sayer, H. G., Longton, G., Bowden, R., Pepe, M. and Storb, R. (1994). Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood, 84, 1328-1332.
18. Winston, D. J., Chandrasekar, P. H., Lazarus, H. M. et al. (1993). Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med, 118, 495-503.
19. Goodman, J. L., Winston, D. J., Greenfield, R. A. et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 326, 845-851
20. Bodey, G. P., Anaissie. E. J., Elting, L. S. et al (1994). Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer, 73, 2099-2106.
21. Goodrich, J. M., Reed, E. C., Mori, M. et al (1991). Clinical features and analysis of risk factors for invasive candidat infection after marrow transplantation. J.I.D., 164, 731-740.
22. Bjerke, J. W., Meyers, J. D. and Bowden, R. A. (1994). Hepatosplenic candidiasis-a contraindication to marrow transplantation? Blood, 84, 2811-2814.
23. Katayama, K., Koizumi, S., Yamagami. M. et al. (1994). Successful peritransplant therapy in children with active hepatosplenic candidiasis. Int J. Hematol, 59, 125-130.